The most dangerous part of sepsis is not the phase of out-of-control inflammation, though that is plenty dangerous. It is the subsequent phase of immunosuppression, when septic individuals are highly susceptible to follow-on infections. Read More
Soleno Therapeutics Inc., of Redwood City, Calif., reported data from a pilot trial testing diazoxide choline controlled-release tablet (DCCR) in 13 patients with Prader-Willi syndrome at the 10th International Meeting of Pediatric Endocrinology in Washington. Read More
CSL Behring LLC, of King of Prussia, Pa., said the FDA approved Privigen (immune globulin intravenous, human, 10 percent liquid) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability. Read More
Summit Therapeutics plc, of Oxford, U.K., said underwriters of its public offering exercised in full their overallotment option to purchase an additional 218,850 American depositary shares (ADSs) at $12 per ADS, increasing the total number of shares in the offering to about 1.7 million. Read More
HONG KONG – Alvogen Korea Ltd. has announced an agreement for exclusive rights to license, sell and market Vivus Inc.'s obesity drug, Qsymia (phentermine/topiramate), in South Korea, a deal expected to shore up the company's strong position in the Korean market while adding to its obesity portfolio, said Petar Vazharov, Alvogen's Asia-Pacific executive vice president. Read More
Zika virus' greatest threat is its preference for developing brain cells. As a result, while infections in adults are mostly harmless – indeed, more often than not, they are asymptomatic – infections in pregnant women can have devastating effects on fetal brain development. Read More
SHANGHAI – The 2017 Healthcare Capital and Connections Summit is an event where American biopharmas, lawyers, bankers and investors come to Shanghai to see for themselves what the China opportunity is all about. The organizers, SPD Silicon Valley Bank, Piper Jaffray and Vivo Capital, do their part to line up a complementary group of Chinese counterparts for them to meet, face to face. Read More
Shares of Mirati Therapeutics Inc. (NASDAQ:MRTX) doubled at their opening Friday morning and spiked to a 15-month high of $12.40 on word that the combination of the company's tyrosine kinase inhibitor (TKI), sitravatinib (MGCD-516), with Opdivo (nivolumab, Bristol-Myers Squibb Co.) showed three confirmed partial responses (PRs) in the first 11 evaluable patients with non-small-cell lung cancer (NSCLC) who had progressed following checkpoint therapy. Read More
DUBLIN – Bavarian Nordic A/S lost half its market value Friday when an interim analysis showed that a phase III trial of its cancer vaccine, Prostvac (rilimogene galvacirepvec/rilimogene glafolivec), was not going to deliver a good result. The trial's independent data monitoring committee recommended that the study in patients with metastatic castration-resistant prostate cancer be stopped for futility. Read More
LONDON – Shares in Santhera Pharmaceutical AG crashed by 58 percent on Friday morning after the EMA gave a thumbs down to Raxone (idebenone) as a treatment for the respiratory complications of Duchenne muscular dystrophy (DMD). Read More
